Article info
PDFOriginal research
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study
- Correspondence to Dr Joanne Chiu, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong; jwychiu{at}hku.hk
Citation
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study
Publication history
- Received April 20, 2021
- Accepted May 17, 2021
- First published May 26, 2021.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.